CONCLUSIONS: Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy.
SCIENTIFIC SIGNIFICANCE: These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child. (Am J Addict 2013; 22:252-254).
PMID: 23617867 [PubMed – in process] (Source: American Journal on Addictions)
Buprenorphine + Naloxone in the Treatment of Opioid Dependence during Pregnancy-Initial Patient Care and Outcome Data.
Previous post: Buprenorphine therapy: an increasing challenge in oral and maxillofacial surgery
Next post: First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland
